You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence
  1. Gina Daubney Garrison
  1. Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA
  1. Correspondence to Gina Daubney Garrison
    Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA; gina.garrison{at}acphs.edu

http://dx.doi.org/10.1136/ebmed.2011.100147

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011;171:770–7.OpenUrlCrossRefPubMedWeb of Science

    Context

    Efficacy of varenicline for tobacco cessation has been attributed to its partial agonist activity at selective nicotinic acetylcholine receptors.1 This mechanism of action is thought to reduce withdrawal symptoms, while competitively occupying receptors linked to reward pathways to decrease smoking enjoyment and intake.1 2 When combined with counselling, varenicline can improve smoking abstinence rates two to threefold.3 4

    Most clinical trials of varenicline initiated therapy 1 week prior to target quit date (TQD).3 4 5 In a ‘proof-of-principle’ study, Hajek et al compared varenicline 1 week versus …

    View Full Text

    Footnotes

    • Competing interests None.